MedPath

GLP-1 administration test for assessing the glucose metabolism and predictive efficacy of the incretin based treatment

Not Applicable
Conditions
Type 2 diabetes mellitus
Registration Number
JPRN-UMIN000010067
Lead Sponsor
Miyazaki university
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Patient with severe complication (proliferative retinopathy, serum cleatinine > 2.0 mg/dL, cerebrovascular disease, and/or ischemic heart diseases), severe liver dysfunction and/or dementia.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Insulin secretion in GLP-1 administration compared to saline administration using meal tolerance test. 2. The relationship between the result of GLP-1 administration test and the changes of HbA1c after incretin based treatment.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath